Plus Therapeutics

Marc Hedrick, President & CEO of Plus Therapeutics (NASDAQ: PSTV), was a guest on Benzinga’s All-Access. Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics with the potential to enhance clinical outcomes in patients with difficult-to-treat...

Marc Hedrick, M.D., President and CEO of Plus Therapeutics (NASDAQ: PSTV) was recently a guest on Benzinga’s All-Access. Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. The company...

Norman LaFrance, MD, CMO & Senior VP, and Melissa Moore, PhD, VP of Clinical Research for Plus Therapeutics Inc. (NASDAQ: PSTV) were recently interviewed by Benzinga. Plus Therapeutics is a clinical stage pharmaceutical company that has developed a radiotherapeutic platform with the potential...

Plus Therapeutics, Inc. (NASDAQ: PSTV) is ending 2022 on a high note after a year of significant clinical progress. Plus Therapeutics is a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers with a focus in central nervous...

At the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, Plus Therapeutics, Inc. (NASDAQ: PSTV) provided a positive update about its ReSPECT clinical trials. The ReSPECT trials are evaluating the safety and effectiveness of rhenium (186Re) obisbemeda in...

Rare Cancer Day on Sept. 30 was an opportunity for many to reflect: What would they give for one more moment with their loved ones?  Most people pass the day without considering the precious gift of life, without counting each opportunity they get to hug and thank the people in their lives....

Sign up for this week’s All Access giveaway here!  Marc Hedrick MD, President and CEO of Plus Therapeutics, Inc (NASDAQ: PSTV), was a guest on Benzinga’s All Access on October 14, 2022. Plus Therapeutics is developing targeted radiotherapeutics, a novel treatment for cancer. The...

Photo by National Cancer Institute on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Pharmaceutical companies around the world have taken innovative and diverse approaches over the past few years...

Photo by ThisisEngineering RAEng on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Plus Therapeutics Inc. (Nasdaq: PSTV) presented positive interim results from its ReSPECT-GBM...

Photo by National Cancer Institute on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. For more than 100 years, radiotherapy has been a cost-effective and essential tool in...

Photo by National Cancer Institute on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. In 1971 when U.S. President Richard Nixon signed the National Cancer Act to declare war on...